Metformin – the newer role of the old medicine - in cancer prevention and treatment!

Dr. Asish Kumar Biswas, Dr. Matin Ahmad Khan, Dr. Md Shadab Alam and Dr. AK Choudhary

Abstract
The potential use of metformin as a novel cancer prevention strategy has generated much excitement in view of its low cost, favourable safety profile, and its potential for biological specificity in disrupting the autonomous growth of cancerous cells. Metformin, a biguanide derivative, is currently the first-line drug for the treatment of type 2 diabetes (T2D) due to its ability to inhibit hepatic gluconeogenesis and trigger glucose uptake in skeletal muscle. Different from other biguanides, metformin is a relatively safe and well-tolerated drug, with acknowledged pharmacokinetics and manageable toxicities. Besides glucose-lowering effect, there is increasing interest in its anticancer potential. A huge amount of epidemiologic evidence shows that metformin exposure may reduce cancer incidence and improve cancer patients’ prognosis. Accumulating preclinical and clinical studies also demonstrate that metformin may not only exert anticancer properties in a spectrum of established malignancies but also have effects in preventing tumor initiation. The mechanisms involved in the antineoplastic effects of metformin are mainly divided into two categories: “indirect effect” resulting from systemic changes in glucose or insulin levels and “direct effect” on tumor cells. The direct anticancer effects of metformin are mainly explained by activation of adenosine monophosphate-activated protein kinase (AMPK) and a reduction in mammalian target of rapamycin (mTOR) signaling, which inhibits protein synthesis and gluconeogenesis. However, metformin may also exert antineoplastic properties in an AMPK-independent manner. The prevalence of diabetess is dramatically increasing worldwide reaching epidemic proportion. Landmark of diabetes, chronic hyperglycemia leads to the development and progression of life-threatening complications, predominantly cardiovascular. The results of several studies indicate that people with diabetes (mainly type 2, T2DM) are also at substantially higher risk of cancer of the pancreas, liver, endometrium, breast, colon, rectum and urinary bladder compared to individuals without this chronic disease. However, the incidence of other types of cancer (e.g., lung, kidney, non-Hodgkin lymphomas) does not seem to be strongly associated with diabetes or the evidence is inconclusive. Interestingly enough, it has been suggested that diabetes is associated with a lower risk for prostate cancer. According to the American Diabetes Association and the American Cancer Society consensus report the relative risks imparted by diabetes are greatest (about two fold or higher) for cancers of the liver, pancreas, and endometrium, and lesser (about 1.2-1.5 fold) for cancers of the colon and rectum, breast, and bladder. Clinical observations indicate that the prevalence of diabetes in newly diagnosed cancer patients ranges from 8% to 18%, suggesting bidirectional association between these two disease. The association of diabetes and cancer was first reported as an incidental finding in 1932. Nowadays, this coexistence is well recognized, however in spite of the intensive studies its mechanism still remains unclear. There is a general agreement that T2DM and cancer share several common potential risk factors (e.g., aging, sex, obesity, physical inactivity, diet, alcohol, and smoking). In T2DM, insulin resistance and hyperinsulinemia (either endogenous due to insulin resistance or induced by administration of exogenous insulin formulations) are considered to be independent risk factors for cancer development. In addition, hyperglycemia-related oxidative stress, accumulation of advanced glycation end products as well as low-grade inflammation may also enhance the risk of malignant transformation. Recent publications have also suggested the link between hypoglycemic medications and cancer. The results of numerous preclinical, epidemiological and clinical studies suggested that metformin use is associated with inhibition of cancer cell growth and proliferation and reduction in all-cancer incidents in comparison with users of other hypoglycemic drugs. In the present work we discuss the proposed mechanism(s) of anticancer effect of metformin as well as preclinical and clinical data suggesting this beneficial effect. We describe the role of metformin in the prevention and treatment of a variety of cancers and summarize the molecular mechanisms that are currently well documented in the ability of metformin as an anticancer agent.

Keywords: Metformin, old medicine, cancer prevention
Introduction
Cancer and diabetes are two of the most common chronic diseases worldwide with a strong association between the two diseases. Substantial evidence exists indicating that the risk of developing and dying from breast cancer is higher in diabetic patients compared to nondiabetic patients, excluding all other diseases. Metformin, a biguanide oral antidiabetic drug, commonly used to treat type 2 diabetes mellitus has aroused much interest in comorbidity (diabetes/cancer) treatment, and emerging evidence from in vitro and epidemiological studies suggests that metformin improves the overall survival for cancer/diabetic comorbidity patients. In vitro experimentation supports metformin as a strong candidate for treatment of breast cancer, where it has been shown to increase breast cancer cell death. However, the use of metformin as a comorbidity treatment, or breast cancer preventative therapy, in retrospective clinical meta-analyses studies is controversial. Metformin, on the one hand, has been shown to decrease cancer incidence and increase survival while on the other hand no such association has been observed in other studies.

Mechanism of Metformin action to inhibit cancer
The exact molecular mechanism of metformin action is not clearly understood and has been hotly debated. Nevertheless, metformin action undisputedly has been shown to increase insulin sensitivity in vivo, resulting in reduced plasma glucose concentrations, increased glucose uptake, and decreased gluconeogenesis. High insulin levels are associated with increased breast cancer risk and poor patient survival outcome. Therefore, metformin directly and indirectly reduces cancer cell proliferation through reduction of insulin levels and blood glucose levels. In the context of breast cancer risk, metformin has been shown to decrease circulating hormones such as androgen and estrogen where elevated levels are linked with postmenopausal breast cancer development. Thus, metformin treatment may serve as a contributory factor in decreasing breast cancer risk.

The concept that cancer cells undergo metabolic reprogramming in favour of glycolysis is generally accepted. Metformin acts by interfering with cellular processes that facilitate insulin signalling and glucose synthesis.

Discussion
Molecular action of Metformin in Cancer Cell
The current proposed anticancer molecular action of metformin is mainly associated with the inhibition of the mammalian target of rapamycin complex 1 (mTORC1). The mTOR pathway plays a pivotal role in metabolism, growth, and proliferation of cancer cell. Metformin is thought to inhibit mTORC1 pathway.

It is believed that systemic effect of metformin manifested by the reduction of circulating level of insulin and insulin-like growth factor 1 (IGF-1) might be associated with anticancer action. Insulin/IGF-1 is involved not only in regulation of glucose uptake but also in carcinogenesis through up-regulation of insulin/IGF receptor signaling pathway. The excessive food consumption (insulin) leads to increased liver production of IGF-1 that binds to IGF-1 receptor and insulin receptor. Then, through insulin receptor substrate (IRS) the signal is transmitted to phosphoinositide 3-kinase (PI3K), and Akt/protein kinase B (PKB) that indirectly activates (not phosphorylates) mTORC1. Additionally, insulin receptor through growth factor receptor-bound protein 2 (GRB2) propagates signal to Ras/Raf/ERK pathway that drives cell growth. Evidences indicate that these pathways play an important role in changes of cellular metabolism that are typical feature of tumor cells. Increased levels of circulating insulin/IGF1 and up-regulation of insulin/IGF receptor signaling pathways were demonstrated to be involved in the formation of many types of cancer. Metformin was found to reduce insulin level, inhibit insulin/IGF signaling pathways, and modify cellular metabolism in normal and cancer cells.

Evidences suggest that the inhibition of mTOR pathway by metformin proceeds dependent and independent on AMP-activated protein kinase (AMPK) activation. AMPK phosphorylates tuberous sclerosis complex protein 2 (TSC2) that inhibits mTORC1 leading to decrease in protein synthesis and cell growth (17). Among the first studies that showed the participation of AMPK activation in antitumor action of metformin were researches performed on breast cancer cells. Dowling et al. showed that compound C, an inhibitor of AMPK, reversed inhibition of initiation of translation evoked by metformin. More recently, Mohammed et al. showed reduction of carcinoma spread in pancreas of transgenic mice fed with metformin. Additionally, pancreatic tissue of mice fed with metformin revealed a significant inhibition of mTOR, and an increase of phosphorylated AMPK and TSC2. However, Gwinn et al. demonstrated that inhibition of mTOR could be independent on TSC2, since AMPK directly phosphorylates the rotor compartment of mTOR.

Several studies identified that liver kinase B1 (LKB1), a major upstream kinase of AMPK, may be involved in...
anticancer action of metformin associated with inhibition of mTOR. *In vitro* and *in vivo* studies revealed that deletion of LKB1 function accelerated proliferation of tumor cell and sensitized them to activators of AMPK such as biguanide Due to the fact that p53 expression and phosphorylation is regulated by AMPK and p53 is involved in cell metabolism and control of cell cycle its participation in metformin action is discussed. Growing evidences from *in vivo* and *in vitro* studies of various cancers revealed that metformin blocked cell cycle in G0/G1 phase with a significant decrease expression of G1 cyclins (including cyclin D1) without changes in p53 status. However, others researches indicated that inhibitory effect on cancer cell growth of metformin was associated with p53 activity. Taking together the results of preclinical studies are inconclusive whether antitumor action of metformin is associated with p53. Some investigators hypothesize that the dose of metformin may determine the effect of metformin. Yi et al. demonstrated on hepatoma cells that low concentration of metformin induced p53-dependent senescence, whereas higher doses induced apoptotic cell death. Inhibition of mTOR by metformin independent on AMPK activation was demonstrated by Memmott et al. in mice lung cancer cells. Metformin evoked inhibition of mTOR pathway with accompanied decreasing activation of IGF-1/insulin receptor, Akt, extracellular signal-regulated kinase (ERK) without AMPK activation. Kalender et al. demonstrated in Drosophilla cells that inhibition of mTOR signaling induced by metformin occurred in the absence of AMPK. They reveal the existence of an alternative TSC1/2-mTOR AMPK-independent pathway mediated by RAG GTPase. Metformin was found to inhibit breast carcinoma cell growth through decreasing level of epidermal growth factor receptor 2 (HER2). This effect was mediated by inhibition of the mTOR effector, p70S6K1. p70S6K is responsible for the phosphorylation of S6 ribosomal protein and thereby protein synthesis at the ribosome. Antiproliferative action of metformin related to enhancement of DNA-damage-inducible transcript 4 protein (DDIT4, REDD1) expression, a negative regulator of mTOR, was reported in prostate cancer cells by Ben Sahra et al. This effect of metformin was also independent on AMPK activation. The results of preclinical studies undoubtedly confirm the efficacy of metformin to inhibit cancer cell growth *in vitro* and to reduce tumor spread in animal models of various cancers. However, it should be stressed that molecular action of metformin is still investigated and seems to be affected by the type of tumor cell line. Metformin and risk of cancer Metformin is the most commonly prescribed drug for T2DM. Its use in diabetes was shown to prevent macrovascular complications to the better extent than other oral hypoglycemic drugs as well as insulin. Additionally, the results of numerous epidemiologic studies repeatedly indicated that T2DM patients receiving metformin, compared to those taking other antidiabetic medications, had a decreased risk of the occurrence of various types of cancers. This observation was also confirmed by numerous meta-analyses that confirmed that metformin reduces cancer incidence by 30-50%. Bowker et al. used databases from Saskatchewan Health (Canada) to examine the association between different therapeutic schedules of diabetes and cancer mortality in T2DM patients. It was observed that in T2DM patients using sulfonylureas (SU) or insulin the risk of cancer-related mortality was significantly increased compared to metformin users. A similar difference in cancer incidence in metformin users compared with SU was also reported by Evans et al. The researchers used databases developed in Tayside (Scotland) to assess the influence of metformin therapy on the risk of cancer in patients with T2DM. They observed that metformin reduced the risk of cancer in patients with T2DM, both before and after adjusting for BMI. Additionally, they suggested the existence of the inverse relation between the dose of metformin and the risk of cancer. Currie et al. performed a retrospective cohort study in 62,809 people older than 40 years, treated in U.K. by general practitioners. Patients were on oral antidiabetic drugs and/or insulin. For the analysis the cohort was subdivided into four groups: metformin monotherapy, sulfonylurea monotherapy, combination therapy with metformin and sulfonylurea, or insulin. Insulin users were further subdivided into glargine, long-acting human insulin, biphasic analogue or human biphasic insulin. The observed risk of cancer in patients treated with basal human insulin alone vs. glargine alone was 1.24. Insulin therapy was associated with an increased risk for colorectal (HR =1.69) and pancreatic cancers (HR =4.63). However, when compared with metformin, this relation was not seen for breast and prostate cancers. Franciosi et al. selected randomized studies comparing metformin and other hypoglycaemic agents as well as observational studies assessing the relation between exposure to metformin and cancer. Altogether, 12 randomized controlled trials and 41 observational studies met the inclusion criteria. They noted that in observational studies there was a significant association of exposure to metformin with the risk of cancer death, all malignancies, liver, colorectal, pancreas, stomach, and esophagus. Interestingly, such a relationship was not seen in randomized trials, what stresses the need for randomized trials to evaluate the efficacy of metformin as an anticancer agent. Another meta-analysis of seventeen observational studies investigated the risk of all cancers and site-specific cancers in people with T2DM. Soranna et al. compared metformin with SU users. The meta-analysis showed that therapy with metformin use was associated with decreased risk for all cancer. Furthermore, except for colorectal cancer, metformin was not associated with any significant effect on the incidence of other cancers, for example, prostate and breast cancers. In a large population-based study, a lower risk of cancer cancers was observed in patients treated with metformin in comparison with those received SU. The duration of diabetes was similar in both groups, but unfortunately the cause of death was not identified. That is why the researchers could not compare the association of the cancer-related mortality between metformin and SU users. Chlebowski et al. assessed the association between diabetes, metformin use, and breast cancer among 68,019 postmenopausal women participating in Women’s Health Initiative clinical trials. Compared with women without diabetes, in diabetic women the incidence of breast cancer was related to diabetes therapy. Diabetic women not treated with metformin had a slightly higher incidence of breast cancer. The association was observed for cancers positive for both estrogen receptor and progesterone receptor as well as those negative for HER2. Home et al. collected data for malignancies in Diabetes Outcome Progression Trial (ADOPT) and Rosiglitazone.
Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) studies. The results did not reveal significant differences in cancer incidence between metformin and rosiglitazone, however the incidence of cancer was slightly higher in SU group. One should remember that the number of malignancies was small in both trials. Zhang et al. pooled the currently available data to examine the association between metformin therapy and colorectal cancer among patients with T2DM. More than 108,161 patients with T2DM were included into analysis, and once again they noted that metformin treatment was associated with a significantly lowest risk of colorectal cancer. Noto et al. calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence in 21,195 diabetic patients. Similarly to the results of other trials they noted that the use of metformin in diabetic patients was associated with significantly lower risks of both cancer incidence and mortality.

The positive correlation between metformin use and incidence of various type cancers was not universally noted by all investigators. Mamta et al. analysed data from 87,600 patients with T2DM. They assessed the incidence of bladder cancer in new users of metformin and SU and did not see any association between metformin use and this type cancer. It is still uncertain, whether the observed increased risk of cancer mortality in diabetic patients are related to a protective effect of metformin or negative effects of other therapies including SU and insulin. Again, if the difference in cancer-related mortality is related to the antidiabetic drugs, it may be associated with either the slower development of the cancer or better response to anticanicancer therapy. Additionally, one should also remember, that there are important differences in the characteristics of patients treated with metformin compared with other antidiabetic agents. These differences may be responsible for the observed differences in cancer incidence. In the United Kingdom metformin users had a higher BMI, a younger age, a lower systolic blood pressure, a lower prevalence of cardiovascular disease, and a higher proportion of aspirin and NSAID use as compared with second-generation SU users at the beginning of therapy.

Clinical evidence with Metformin in prevention and therapy of Cancer

Biguanides were used in oncology more than 40 years ago as “metabolic rehabilitation” in breast, colorectal, or gastric cancers patients. The therapy with biguanides used with caloric restriction resulted in diminished tumor development and lower incidence of metastases. However, until now we do not have conclusive data on the role of metformin neither in cancer prevention nor the therapy both in diabetic and non-diabetic populations.

Several studies assessed the influence of metformin on metabolic status in cancer patients with and without diabetes. It was observed in nondiabetic woman that in the early stage breast cancer metformin reduced fasting insulin by 22% and improved several metabolic parameters. In a randomized study in women with breast cancer, Campagnoli et al. observed that doses of metformin used routinely in diabetes decreased testosterone and insulin levels as well as several indices of insulin resistance. In another study in non-diabetic women with breast cancer the therapy with metformin resulted not only in reduced number of Ki67-positive cancer cells but also in changes in gene expression of molecules involved in the mTOR and AMPK pathways. In a randomized study, Hosono et al. showed that compared to control group metformin in small doses (250 mg/day) reduced colorectal aberrant crypt foci (regarded as surrogate marker for colorectal cancer) by 40% in non-diabetic patients. Jiralerspong et al. observed 2,529 females with breast cancer. They noted increased incidence of complete response rates in metformin group, both in patients with and without diabetes however, despite the increased incidence of complete response rates, metformin did not significantly improve survival. Margel et al. assessed the relation between duration of metformin therapy after prostate cancer diagnosis and mortality in patients with diabetes the data were obtained from several databases in Ontario (Canada). In the cohort consisting of 3,837 patients, they noted that the longer duration of metformin treatment after diagnosis of prostate cancer was associated with a significant decrease not only in the risk of cancer-specific but also in all-cause mortality.

Metformin was also used as adjuvant therapy in cancer patients, and most of the cancer clinical trials of metformin use the same doses typically used to treat diabetes.

Conclusion

The observation that metformin reduces cancer risk in diabetic patients has raised considerable interest and has stimulated a variety of studies. Preclinical evidence suggests that metformin appears to inhibit the proliferation and growth of certain types of cancer. Results of numerous clinical studies, although inconclusive, indicate that metformin use, and possibly cumulative duration of therapy and cumulative dose, is associated not only with decreased incidence of cancer in diabetic population, but also with the better outcome in cancer patients. Considering the possible variations in response to metformin in cancer patients it seems crucial to identify target populations for its use. However, factors contributing to better outcome in metformin users, such as genetic polymorphisms, are still to be elucidated the definite data on the efficacy of metformin as neoadjuvant therapy in cancer patients is lacking. There are numerous trials underway in prostate cancer patients receiving androgen deprivation therapy as well as in patients with small benign thyroid nodules and insulin resistance. Altogether, there are currently more than 100 ongoing or upcoming clinical studies assessing the role of metformin in the therapy cancer the vast majority of current trials assess the usefulness of metformin in cancer treatment, while several trials evaluate metformin in cancer prevention. Their results will permit to assess the place of metformin in cancer prevention and therapy, and define the target populations in the nearest future.

References


35. A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available online: www.ClinicalTrials.gov